JP2016094424A5 - - Google Patents

Download PDF

Info

Publication number
JP2016094424A5
JP2016094424A5 JP2015229465A JP2015229465A JP2016094424A5 JP 2016094424 A5 JP2016094424 A5 JP 2016094424A5 JP 2015229465 A JP2015229465 A JP 2015229465A JP 2015229465 A JP2015229465 A JP 2015229465A JP 2016094424 A5 JP2016094424 A5 JP 2016094424A5
Authority
JP
Japan
Prior art keywords
seq
region
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015229465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016094424A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016094424A publication Critical patent/JP2016094424A/ja
Publication of JP2016094424A5 publication Critical patent/JP2016094424A5/ja
Pending legal-status Critical Current

Links

JP2015229465A 2009-10-14 2015-11-25 EphA3に対する抗体 Pending JP2016094424A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25166809P 2009-10-14 2009-10-14
US61/251,668 2009-10-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012534368A Division JP2013508292A (ja) 2009-10-14 2010-10-14 EphA3に対する抗体

Publications (2)

Publication Number Publication Date
JP2016094424A JP2016094424A (ja) 2016-05-26
JP2016094424A5 true JP2016094424A5 (OSRAM) 2016-10-06

Family

ID=43499991

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012534368A Pending JP2013508292A (ja) 2009-10-14 2010-10-14 EphA3に対する抗体
JP2015229465A Pending JP2016094424A (ja) 2009-10-14 2015-11-25 EphA3に対する抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012534368A Pending JP2013508292A (ja) 2009-10-14 2010-10-14 EphA3に対する抗体

Country Status (11)

Country Link
US (2) US8664365B2 (OSRAM)
EP (1) EP2488554B1 (OSRAM)
JP (2) JP2013508292A (OSRAM)
CN (1) CN102666589B (OSRAM)
AU (1) AU2010313621C1 (OSRAM)
CA (1) CA2777068C (OSRAM)
DK (1) DK2488554T3 (OSRAM)
ES (1) ES2743558T3 (OSRAM)
PL (1) PL2488554T3 (OSRAM)
PT (1) PT2488554T (OSRAM)
WO (1) WO2011053465A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2558121A4 (en) * 2010-04-01 2014-01-08 Kalobios Pharmaceuticals Inc EPHA3 ANTIBODY FOR THE TREATMENT OF MULTIPLE MYELOMES
CA2802723A1 (en) * 2010-06-18 2011-12-22 Kalobios Pharmaceuticals, Inc. Detection of epha3 as a marker of the presence of a solid tumor
CA2844674A1 (en) 2011-08-12 2013-02-21 Kalobios Pharmaceuticals, Inc. Methods of treating hematological proliferative disorders by targeting epha3 expressed on aberrant vasculature in bone marrow
PH12019501393B1 (en) * 2013-08-01 2022-09-07 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
CN108368174B (zh) 2015-11-23 2023-04-14 戊瑞治疗有限公司 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
EP3512883A1 (en) * 2016-09-13 2019-07-24 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
BR112019023898A2 (pt) 2017-05-16 2020-06-09 Five Prime Therapeutics Inc método para tratamento de câncer gástrico, uso de um anticorpo e composição
WO2019165982A1 (en) * 2018-02-28 2019-09-06 WuXi Biologics Ireland Limited Monoclonal antibody against human lag-3, method for preparing same, and use thereof
CN114787190A (zh) * 2019-10-09 2022-07-22 昆士兰医学研究所理事会 靶向epha3及其用途
US12139544B2 (en) 2019-11-08 2024-11-12 Mayo Foundation For Medical Education And Research EphA3 directed CAR-T cells for treatment of tumors
WO2022087484A1 (en) * 2020-10-23 2022-04-28 Williams Katherine L Antibodies to coronavirus sars-cov-2
JP7726496B2 (ja) * 2021-08-06 2025-08-20 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー 新規な抗EphA2キメラ抗原受容体及びそれを発現する免疫細胞

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
ES2230537T3 (es) 1991-06-21 2005-05-01 The Walter And Eliza Hall Institute Of Medical Research Una tirosina quinasa de tipo receptor (quinasa de tipo eph/elk hunaba-henki y uso de la misma.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
NO175798C (no) 1992-07-22 1994-12-07 Sinvent As Fremgangsmåte og anordning til aktiv stöydemping i et lokalt område
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
DE60114830T2 (de) 2000-06-28 2006-08-03 Glycofi, Inc. Verfahren zur herstellung modifizierter glycoproteine
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CA2799805C (en) 2002-03-19 2016-05-17 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
KR100980065B1 (ko) 2002-09-27 2010-09-03 젠코어 인코포레이티드 최적화된 Fc 변이체 및 그의 제조 방법
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
EP1778726A4 (en) 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
WO2006052409A2 (en) * 2004-10-23 2006-05-18 Case Western Reserve University Peptide and small molecule agonists of epha and their uses
EP1824987B1 (en) 2004-11-16 2013-08-21 KaloBios Pharmaceuticals, Inc. Immunoglobulin variable region cassette exchange
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008060092A1 (en) 2006-11-17 2008-05-22 Sang Yun Park Rotative force generator
AU2008226905C1 (en) 2007-03-08 2014-11-06 Humanigen, Inc. EphA3 antibodies for the treatment of solid tumors
CL2008002782A1 (es) 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
JP5876728B2 (ja) 2009-03-06 2016-03-02 カロバイオス ファーマシューティカルズ インコーポレイティッド EphA3に対する抗体を用いた、白血病および慢性骨髄増殖性疾患の治療方法

Similar Documents

Publication Publication Date Title
JP2016094424A5 (OSRAM)
JP2013508292A5 (OSRAM)
JP2015520758A5 (OSRAM)
JP2016536361A5 (OSRAM)
JP2015534579A5 (OSRAM)
JP2018506277A5 (OSRAM)
EP4435009A3 (en) Claudin6 antibodies and methods of treating cancer
JP2018534933A5 (OSRAM)
JP2017535257A5 (OSRAM)
JP2017507652A5 (OSRAM)
JP2017529838A5 (OSRAM)
JP2011514150A5 (OSRAM)
RU2019111722A (ru) Антитела против siglec-15 и способы их применения
JP2015503909A5 (OSRAM)
JP2020536109A5 (OSRAM)
JP2014511179A5 (OSRAM)
JP2016188209A5 (OSRAM)
JP2017515815A5 (OSRAM)
JP2009521496A5 (OSRAM)
JP2014158469A5 (OSRAM)
RU2016100892A (ru) Антитела против tweakr и их применение
FI3805268T3 (fi) Vasta-aine joka sitoo ErbB-2:ta ja ErbB-3:a
JP2010526028A5 (OSRAM)
JP2011506483A5 (OSRAM)
JP2018529661A5 (OSRAM)